AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Graphs     Help
Perf. 1W: -9.22%- Perf. 1M: -10.5%- Perf. 3M: -32.5%- Perf Ytd: -36.6%
10 day relative perf. to stoxx600: -6.22%- 20 day relative perf. to stoxx600: -9.90%